BACKGROUND: Recent studies have shown that C-reactive protein (CRP) may be associated with breast cancer. The purpose of this study is to summarize the predictive role of CRP for survival in breast cancer as shown in all available studies worldwide. METHODS: Related studies were identified and evaluated for quality through multiple search strategies. Data were collected from studies comparing overall, cancer-specific, and disease-free survival (OS, CSS, and DFS) in patients with elevated CRP levels and those having lower levels. Studies were pooled, and combined hazard ratios (HRs) of CRP for survival were calculated. RESULTS: A total of 10 studies (n=4,502) were included for this meta-analysis (9 for OS, 3 for CSS, and 3 for DFS). For overall and disease-free survival, the pooled HRs of CRP were significant at 1.62 (95% confidence interval [95% CI], 1.20-2.18) and 1.81 (95% CI, 1.44-2.26), respectively. For cancer-specific survival, the pooled HR in higher CRP expression in breast cancer was 2.08 (95% CI, 1.48-2.94), which could strongly predict poorer survival in breast cancer. CONCLUSIONS: CRP has a critical prognostic value in patients with breast cancer as an inflammation biomarker.
BACKGROUND: Recent studies have shown that C-reactive protein (CRP) may be associated with breast cancer. The purpose of this study is to summarize the predictive role of CRP for survival in breast cancer as shown in all available studies worldwide. METHODS: Related studies were identified and evaluated for quality through multiple search strategies. Data were collected from studies comparing overall, cancer-specific, and disease-free survival (OS, CSS, and DFS) in patients with elevated CRP levels and those having lower levels. Studies were pooled, and combined hazard ratios (HRs) of CRP for survival were calculated. RESULTS: A total of 10 studies (n=4,502) were included for this meta-analysis (9 for OS, 3 for CSS, and 3 for DFS). For overall and disease-free survival, the pooled HRs of CRP were significant at 1.62 (95% confidence interval [95% CI], 1.20-2.18) and 1.81 (95% CI, 1.44-2.26), respectively. For cancer-specific survival, the pooled HR in higher CRP expression in breast cancer was 2.08 (95% CI, 1.48-2.94), which could strongly predict poorer survival in breast cancer. CONCLUSIONS:CRP has a critical prognostic value in patients with breast cancer as an inflammation biomarker.
Authors: S Casla; P Hojman; I Márquez-Rodas; S López-Tarruella; Y Jerez; R Barakat; M Martín Journal: Clin Transl Oncol Date: 2014-06-04 Impact factor: 3.405
Authors: Avonne E Connor; Richard N Baumgartner; Kathy B Baumgartner; Christina M Pinkston; Stephanie D Boone; Esther M John; Gabriela Torres-Mejía; Lisa M Hines; Anna R Giuliano; Roger K Wolff; Martha L Slattery Journal: Mol Carcinog Date: 2014-10-22 Impact factor: 4.784
Authors: Herbert I Hurwitz; Nikhil Uppal; Stephanie A Wagner; Johanna C Bendell; J Thaddeus Beck; Seaborn M Wade; John J Nemunaitis; Philip J Stella; J Marc Pipas; Zev A Wainberg; Robert Manges; William M Garrett; Deborah S Hunter; Jason Clark; Lance Leopold; Victor Sandor; Richard S Levy Journal: J Clin Oncol Date: 2015-09-08 Impact factor: 44.544
Authors: Darren R Brenner; Dominique Scherer; Kenneth Muir; Joellen Schildkraut; Paolo Boffetta; Margaret R Spitz; Loic Le Marchand; Andrew T Chan; Ellen L Goode; Cornelia M Ulrich; Rayjean J Hung Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-24 Impact factor: 4.254